Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention | Zendy

Marco Valgimigli | Zendy; Gianluca Campo | Zendy; Nicoletta De Cesare | Zendy; Emanuele Meliga | Zendy; Pascal Vranckx | Zendy; Alessandro Furgieri | Zendy; Dominick J. Angiolillo | Zendy; Manel Sabaté | Zendy; Martial Hamon | Zendy; Alessandra Repetto | Zendy; Salvatore Colangelo | Zendy; Salvatore Brugaletta | Zendy; Giovanni Parrinello | Zendy; Gianfranco Percoco | Zendy; Roberto Ferrari | Zendy

Open Access

Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention

Author(s) -

Marco Valgimigli,

Gianluca Campo,

Nicoletta De Cesare,

Emanuele Meliga,

Pascal Vranckx,

Alessandro Furgieri,

Dominick J. Angiolillo,

Manel Sabaté,

Martial Hamon,

Alessandra Repetto,

Salvatore Colangelo,

Salvatore Brugaletta,

Giovanni Parrinello,

Gianfranco Percoco,

Roberto Ferrari

Publication year - 2009

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.833236

Subject(s) - tirofiban , medicine , clopidogrel , aspirin , cardiology , placebo , coronary artery disease , ticlopidine , angioplasty , clinical endpoint , acute coronary syndrome , relative risk , loading dose , platelet , platelet aggregation inhibitor , percutaneous coronary intervention , anesthesia , confidence interval , randomized controlled trial , myocardial infarction , alternative medicine , pathology

Inhibition of platelet aggregation after aspirin or clopidogrel intake varies greatly among patients, and previous studies have suggested that poor response to oral antiplatelet agents may increase the risk of thrombotic events, especially after coronary angioplasty. Whether this reflects suboptimal platelet inhibition per se, which might benefit from more potent antiplatelet agents such as tirofiban, is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research